Pharmaceutical company Ipsen will commence a Phase II, proof-of-concept study of tasquinimod in four different cancer indications.
The study is designed to assess the safety and efficacy of tasquinimod in advanced or metastatic hepato-cellular, ovarian, renal cell and gastric carcinomas in patients already treated with standard anti-tumor therapies.
Go deeper with GlobalData
Ipsen R&D executive vice president and chief scientific officer Claude Bertrand said tasquinimod should be assessed beyond prostate cancer due to its unique mode of action.
"We hope that this innovative, proof-of-concept study in oncology will generate data on tasquinimod’s biological and clinical activity and safety profile supporting further clinical development in high unmet medical need diseases," Bertrand said.
The multi-centre, open-label, early stopping design, proof of concept study will measure the clinical activity of Tasquinimod by the section of patients with progression free survival at pre-defined time-points.
Tasquinimod’s immunomodulatory and anti-angiogeneic properties are applicable in addressing unmet medical need in a range of carcinomas.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUnder a co-development agreement signed in April 2011, Ipsen gained exclusive rights from Active Biotech to commercialise tasquinimod worldwide, except for North and South America and Japan where Active Biotech preserved all commercial and marketing rights.
